6 replies to this topic

[pinballwizard]

http://www.newscient...le.ns?id=dn7342

New drug offers jitter-free mental boost

A compound dubbed CX717, a member of the new class called ampakines, significantly improved performance on tests of memory, attention, alertness, reaction time and problem solving in healthy men deprived of sleep.

...

During the trial, 16 healthy young males were randomly assigned to take either 100 milligrams, 300 mg or 1000 mg of the drug, or given a placebo. By the end of the experiment, each volunteer had been assigned to all of the experimental groups, thus producing his own control scores.

The volunteers were hooked up to EEGs to measure brain wave activity and were put through a battery of tests. The first round of each session was after a good night’s sleep. Thereafter, they were tested every few hours throughout a sleepless night and into the next morning, during a total of 27 hours without rest.

The researchers found that the drug significantly improved performance on tests. And taking more of the drug improved performance for longer.

Ampakines work by binding to particular receptors in the brain, called AMPA-type glutamate receptors. This boosts the activity of glutamate, a neurotransmitter, and makes it easier to encode memory and to learn. And because of their short half-life - hours in this case - ampakines have few side effects.

The drug, which will have to undergo further clinical trials before being approved, is being considered as a possible treatment for narcolepsy, jet lag, attention-deficit hyperactivity disorder (ADHD) and even Alzheimer’s disease.
....

Where can we get this?

[haveblue]

CX717 causes specific regional cerebral blood flow changes to improve cognition
Feb 1, 2005, 10:04

By Akanksha,Pharmacology Correspondent,
The U.S. Food and Drug Administration (FDA) has accepted the Cortex Pharmaceuticals',CX717 investigational new drug (IND) application to initiate pilot Phase II clinical trials in the United States.

CX717 is being developed as a potential treatment for cognitive dysfunction that can arise from a variety of neuropsychiatric conditions including Alzheimer’s disease,attention-deficit hyperactivity disorder(ADHD),and sleep disorders.

"We are pleased by the timely response by the FDA and their permission for us to proceed with the proposed clinical investigation. In our IND application we submitted Phase I safety and pharmacokinetic data from nearly 100 healthy volunteers who were dosed with CX717 in studies that took place at Quintiles’ Drug Research Unit in London," said Roger G. Stoll, Ph.D., Chairman, President and CEO of Cortex.

"CX717 was both well tolerated across a wide range of doses and exhibited simple, linear and predictable pharmacokinetic properties in these studies. We were also able to confirm that the drug had a 9 -10 hour half-life in these subjects, and that may provide Cortex with an opportunity to provide patients with a once a day therapy. We are appreciative of the efforts put forth by Cortex’s scientists and Quintiles, a large and well-respected global clinical research organization."

The first study of CX717 in the U.S. will be a double-blind, placebo-controlled study using Positron Emission Tomography (PET) imaging to determine the response of patients with Alzheimer’s disease, as well as healthy elderly volunteers, to CX717.

The study will look for changes in regional cerebral blood flow, which is a marker of brain activity. A positive effect with CX717 will build confidence that CX717 may have a therapeutic benefit in patients with Alzheimer’s disease.

In a similar study paradigm in primates, CX717 demonstrated specific activity in the prefrontal cortex, hippocampus and visual cortex, which are the key brain regions needed to improve memory, cognition and attention.The study in Alzheimer’s disease will be followed shortly thereafter with an Attention-Deficit/Hyperactivity Disorder (ADHD) trial.

CX717 is Cortex’s exclusive compound and excluded from existing partnerships. These studies, in addition to the currently ongoing sleep deprivation study in the U.K, are very important indications to the future of the Company.

[worldeater]

It was just slashdotted: clickme

[vajra78]

Just roll on up to Cortex pharmiceuticals, and say "Hey! give me some of of that good stuff your working on". You can't get it, but you can buy there stock if you believe there product is as good as they say it is. I beleive its going at low price right now.

[vajra78]

oh good, there stock went back up.